Understanding immune responses to COVID-19 and influenza vaccines
Official title: Project 2
Funded at Washington University · NIH-10824580 · Data updated 2026-11-12
This study is looking at how COVID-19 and flu vaccines help your immune system, especially in your lungs, and it’s for adults who have either been vaccinated or infected, to see how their immune responses compare and how we can make vaccines even better against respiratory viruses.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | September 4, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $699,043 |
| NIH project number | 1U19AI181103-01 |
| Project ID | NIH-10824580 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who have received COVID-19 vaccinations or have been infected with the virus.
✕Less likely to help
Patients who are not adults or those who have not been vaccinated or infected with COVID-19 may not benefit from this research.
What this research studies
This research investigates how COVID-19 and influenza vaccines affect the immune system, particularly focusing on mucosal immunity in the respiratory tract. It aims to understand the differences in immune responses generated by vaccination compared to natural infection. By analyzing clinical samples from adults who have been vaccinated or infected, the study will explore the quality of antibodies and T cell responses. This approach could provide insights into improving vaccine effectiveness against respiratory viruses.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective vaccines that better protect against respiratory infections.
How similar studies have gone: Previous research has shown that understanding immune responses can lead to significant advancements in vaccine development, indicating potential success for this approach.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Diamond, Michael S — Washington University
- Study coordinator: Diamond, Michael S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.